Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events - Cyprium (Details)

v3.23.3

Subsequent Events - Cyprium (Details) - Subsequent Events - Cyprium $ in Millions	Nov. 15, 2023 USD ($) D
Subsequent Events
Ownership percentage retained over any FDA priority review voucher that may be issued at NDA approval for CUTX	100.00%
Sentynl APA \| Annual net sales up to $75 million
Subsequent Events
Royalty on net sales to be received (in percent)	3.00%
Contingent liability	$ 75.0
Sentynl APA \| Annual net sales between $75 million and $100 million
Subsequent Events
Consideration Transferred	$ 100.0
Royalty on net sales to be received (in percent)	8.75%
Contingent liability	$ 75.0
Sentynl APA \| Annual net sales in excess of $100 million
Subsequent Events
Consideration Transferred	$ 100.0
Royalty on net sales to be received (in percent)	12.50%
Sentnyl
Subsequent Events
Contingent liability	$ 4.5
Sentnyl \| Sentynl APA
Subsequent Events
Number of days to assume control over development of CUTX-101 in the event that CUTX-101 NDA approval has not been obtained \| D	45
Consideration Transferred	$ 133.5

- Definition

Represents the number of days to assume control over development of CUTX-101 in the event that CUTX-101 NDA approval has not been obtained by period end date.

+ References

No definition available.

+ Details

Name:	fbio_AssetsAcquisitionNumberOfDaysToAssumeControlOverDevelopmentOfCutx101
Namespace Prefix:	fbio_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the percentage of ownership to be retained over any FDA priority review voucher that may be issued at NDA approval for CUTX-101.

+ References

No definition available.

+ Details

Name:	fbio_AssetsAcquisitionOwnershipPercentageToBeRetainedOverAnyFdaPriorityReviewVoucher
Namespace Prefix:	fbio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the percentage of royalty to be received on net sales under asset purchase agreement.

+ References

No definition available.

+ Details

Name:	fbio_AssetsAcquisitionPercentageOfRoyaltyOnNetSales
Namespace Prefix:	fbio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 55
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479908/805-50-55-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480060/805-50-25-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480027/805-50-30-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480027/805-50-30-2

+ Details

Name:	us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of liability recognized from contingent consideration in asset acquisition.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 15
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480123/805-50-15-3

+ Details

Name:	us-gaap_AssetAcquisitionContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481674/830-30-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483399/855-10-50-2

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ConsolidatedEntitiesAxis=fbio_CypriumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=fbio_SentynlDevelopmentAndAssetPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=fbio_AnnualNetSalesUpTo75MillionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=fbio_AnnualNetSalesBetween75MillionAnd100MillionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=fbio_AnnualNetSalesInExcessOf100MillionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=fbio_SentynlTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: